The raised guidance and accelerating NGS growth signal improving fundamentals. Watch for initial MRD revenue contribution in Q2 and any updates on clinical adoption of RaDaR ST.
Price Chart
Executive Summary
NeoGenomics reported Q1 2026 revenue of $187M (+11% YoY), beating consensus of $184.5M, and raised full-year revenue guidance to $797-803M (from $793-801M). GAAP EPS of -$0.13 missed the Street consensus of -$0.08, but adjusted EPS turned positive at $0.01. The company highlighted strong clinical revenue growth (14%), NGS growth (26%), and the launch of the RaDaR ST MRD assay.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $186.7M, up 11% YoY, above $184.5M consensus
- GAAP net loss of $17.1M improved 34% from $25.9M in Q1 2025
- Adjusted EBITDA $9.0M, up 27% YoY from $7.1M
- Raised FY2026 revenue guidance to $797-803M from $793-801M
- Clinical revenue grew 14%, NGS volume up 26%
- Launched RaDaR ST MRD assay in February 2026
- Cash and marketable securities $146M at quarter end
Financial Impact
Revenue beat by $2.2M (+1.2%), adjusted EBITDA up 27% YoY, and full-year guidance raised slightly
Risk Factors
- Still generating GAAP net losses; path to profitability uncertain
- Cash burn continues ($8.1M operating cash outflow in Q1)
- Competition in MRD testing from Guardant, Natera
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001077183-26-000022 |
| Document: neo-20260428.htm | 0001077183-26-000022 |
| Document: 0001077183-26-000022-index-headers.html | 0001077183-26-000022 |
| Document: 0001077183-26-000022-index.html | 0001077183-26-000022 |
| Document: 0001077183-26-000022.txt | 0001077183-26-000022 |
| 8-K Data (Synthetic) | 0001077183-26-000022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 8-K | $16.51 | awaiting T+60 | — | $16.69 (+1.12%) |
Jul 20, 2026 14w ago | 8-K | $14.45 $16.66 | ▲ +15.29% | ▲ +11.32% | $16.69 (+15.50%) |
May 22, 2026 22w ago | 8-K | $9.27 $16.66 | ▲ +79.67% | ▲ +76.94% | $16.69 (+80.04%) |
Apr 28, 2026 25w ago | 8-K | $8.96 $13.89 | ▲ +55.02% | ▲ +50.91% | $16.69 (+86.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers